Internal medicine, Oncology, Lung cancer, Crizotinib and Anaplastic lymphoma kinase are his primary areas of study. His Internal medicine research incorporates themes from Gastroenterology and Surgery. D. Ross Camidge combines subjects such as Clinical trial, Phases of clinical research, Radiation therapy and Immunology with his study of Oncology.
D. Ross Camidge has researched Lung cancer in several fields, including Gene rearrangement, KRAS, Targeted therapy, Disease and EGFR inhibitors. D. Ross Camidge interconnects ROS1, Progression-free survival and Tyrosine-kinase inhibitor in the investigation of issues within Crizotinib. In his study, Molecular biology and Epidermal growth factor receptor is strongly linked to Cancer research, which falls under the umbrella field of Anaplastic lymphoma kinase.
D. Ross Camidge spends much of his time researching Internal medicine, Oncology, Lung cancer, Crizotinib and Cancer research. His Internal medicine study frequently links to adjacent areas such as Surgery. Within one scientific family, he focuses on topics pertaining to Adverse effect under Oncology, and may sometimes address concerns connected to Pharmacokinetics.
His Lung cancer research integrates issues from KRAS, Carcinoma and Adenocarcinoma. His Crizotinib research focuses on Anaplastic lymphoma kinase and how it connects with Gene rearrangement. His biological study spans a wide range of topics, including Epidermal growth factor receptor, Tyrosine kinase, Mutant, Tyrosine-kinase inhibitor and ROS1.
His primary areas of investigation include Internal medicine, Oncology, Lung cancer, Crizotinib and Cancer research. His research investigates the connection between Internal medicine and topics such as Gastroenterology that intersect with issues in EGFR inhibitors. D. Ross Camidge works in the field of Oncology, namely ALK inhibitor.
The Non small cell and Anaplastic lymphoma kinase research he does as part of his general Lung cancer study is frequently linked to other disciplines of science, such as Text mining, therefore creating a link between diverse domains of science. D. Ross Camidge has researched Crizotinib in several fields, including Phases of clinical research and Exon. His studies deal with areas such as ROS1, Antibody, Tyrosine-kinase inhibitor and non-small cell lung cancer as well as Cancer research.
D. Ross Camidge spends much of his time researching Lung cancer, Internal medicine, Oncology, Crizotinib and Cancer research. His work on Anaplastic lymphoma kinase and ROS1 is typically connected to In patient as part of general Lung cancer study, connecting several disciplines of science. His studies in Oncology integrate themes in fields like Targeted therapy, Radiation therapy and Hazard ratio.
D. Ross Camidge works in the field of Crizotinib, focusing on Ceritinib in particular. His Ceritinib research is multidisciplinary, relying on both Gastroenterology, Lorlatinib and Response Evaluation Criteria in Solid Tumors. His Cancer research research incorporates themes from Pembrolizumab, Atezolizumab, Apatinib, Regimen and Bevacizumab.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw.
The New England Journal of Medicine (2010)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto.
The New England Journal of Medicine (2013)
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge.
The New England Journal of Medicine (2014)
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Solange Peters;D. Ross Camidge;Alice T. Shaw;Shirish Gadgeel.
The New England Journal of Medicine (2017)
Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw;Dong Wan Kim;Ranee Mehra;Daniel S W Tan.
The New England Journal of Medicine (2014)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski.
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate.
Lancet Oncology (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele;Amanda B. Pilling;Dara L. Aisner;Tatiana G. Kutateladze.
Clinical Cancer Research (2012)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely.
Lancet Oncology (2011)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge;William Pao;Lecia V. Sequist.
Nature Reviews Clinical Oncology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: